Cell therapy · developed by Lisata Therapeutics
CLBS16 consists of autologous CD34+ cells mobilized with G-CSF and collected from the patient's own blood. It is studied in coronary microvascular dysfunction, a disease of the small coronary arteries.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04614467 | Phase 2 | Coronary Microvascular Dysfunction | Terminated | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Coronary Microvascular DiseaseCoronary Microvascular DysfunctionMicrovascular Coronary Artery Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →